While several recent studies have indicated that LARP1 associates with 5’TOP mRNAs through their TOP sequences or polyA tails (Aoki et al., 2013; Lahr et al., 2015), the comprehensive identity and sequence characteristics of mRNAs that preferentially interact with LARP1 have not been defined. To address this gap, we performed PAR-CLIP of endogenous LARP1 in HEK293T cells in the presence or absence of an mTOR inhibitor (PP242), followed by deep sequencing of the LARP1-bound RNA substrates (The data set was deposited: GEO: GSE59599). One advantage of PAR-CLIP over conventional UV crosslinking methodologies is the signature of specific T-to-C conversions in the resulting sequencing reads that mark where the incorporated 4-thiouracil of RNAs form covalent linkages with the interacting protein (Hafner et al., 2010). Sequenced reads were mapped using Bowtie (Langmead et al., 2009) to the human transcriptome, clustered to derive LARP1 binding sites, and filtered to retain clusters containing 0–2 T-to-C conversion events and passing an empirically-derived reads per million mapped reads (RPM) threshold (details in Materials and methods; Figure 1—figure supplement 1A; Supplementary file 1). In parallel, replicate mRNA-seq experiments were performed in the presence or absence of PP242 to quantify gene expression and normalize LARP1 binding sites to mRNA abundance levels. We identified 1200 and 1,900 LARP1 binding sites on 1000 and 1500 mRNAs in the presence or absence of PP242, respectively (Figure 1—figure supplement 1A and B).

Gene ontology (GO) term enrichment analysis of genes bound by LARP1 in growing conditions revealed enrichment for terms related to translation. LARP1 was bound to 137 translation-related genes, including 42 genes encoding ribosomal proteins (RP), as well as genes involved in cellular differentiation and development (Figure 1A; Supplementary file 2). Under mTOR-inactive conditions, more (230) translation-related genes were bound by LARP1, including 94 RP-encoding genes (Figure 1A; Supplementary file 2). These results indicate that LARP1 substrates are enriched for mRNAs encoding factors involved in translation, and that this interaction is enhanced under conditions of mTOR inactivation.

Figure 1 with 1 supplement see all

Download asset Open asset

To identify where LARP1 binds across a transcript, we summed LARP1 binding coverage across the 5’UTR, CDS, and 3’UTR regions of its targets, which were separated into non-translation-related (non-TR) genes, translation-related (TR) genes, and the subset of TR genes encoding RPs (Figure 1B; Supplementary file 3). Strikingly, LARP1 binding at 5’UTRs of TR genes more than doubled upon mTOR-inactivation, and binding on RP genes increased from 0% to 17% (Figure 1B). To further explore this observation, we plotted the accumulation of LARP1 binding under growing and mTOR-inactive conditions along normalized gene lengths (Figure 1C). Across non-TR mRNAs, LARP1 preferentially associated with CDSs and 3’UTRs, but was almost completely absent from 5’UTRs. In contrast, LARP1 bound most strongly to 3’UTRs of TR and RP mRNAs under growing conditions. Importantly, under conditions of mTOR inactivation, LARP1 accumulated at 5’UTRs, with the majority of 5’UTR binding occurring on RP transcripts (Figure 1C).

Since LARP1 regulates PES-containing mRNAs, including 5’TOP sequences, we searched the 58 and 92 5’UTR LARP1 binding sites under growing and mTOR-inactive conditions, respectively, for a consensus motif using MEME. We identified six consecutive pyrimidines in all 5’UTR LARP1 binding sites, suggesting that LARP1 binds directly to PESs (Figure 1D). Surprisingly, 5’UTR LARP1 binding sites rarely overlapped with 5’TOP sequences, which are located at the 5’-most end of 5’UTRs; instead, LARP1 binds predominantly at the 3’-most end of 5’UTRs (Figure 1C and H; Supplementary file 4). In fact, 5’TOP-containing 5’UTRs bound by LARP1 are more pyrimidine-rich at their 3’ ends than those not bound by LARP1 (Figure 1E). To confirm that LARP1 binds PESs within target 5’UTRs, we compared pyrimidine-richness of LARP1-bound regions to non-LARP1-bound regions of these 5’UTRs and observed a significantly higher proportion of pyrimidines in LARP1-bound regions under both growing (Welch’s two-tailed t-test: p=1.4e-15) and mTOR-inactive (p=1.2e-18) conditions (Figure 1F). Taken together, our data suggest that LARP1 specifically recognizes and binds PESs at the 3’-end of 5’UTRs for a subset of TR and RP transcripts and that LARP1 is not a genuine 5’TOP RNA binding protein (RBP) in vivo.

LARP1 also binds CDSs of non-TR genes and 3’UTRs of TR and RP mRNAs. We identified GA-rich motifs in 9–15% of these sites under both conditions (Figure 1—figure supplement 1C). LARP1-bound 3’UTR regions are slightly, but significantly, enriched for higher G-content than non-LARP1-bound regions on the same 3’UTRs (Figure 1—figure supplement 1D). These motifs are similar to ones identified for RRM domain-containing RBPs in a recent systematic in vitro study characterizing the sequence-specific recognition sites for RBPs across 24 eukaryotes (Ray et al., 2013), suggesting a possible role of LARP1’s RRM domain (Bayfield et al., 2010) to interact with CDSs and 3’UTRs.

The relationship between LARP1 binding and decreases in translational efficiency (TE) upon mTOR inactivation are paralleled in mouse embryonic fibroblasts. We obtained measurements of changes in mouse transcript TE upon treatment of cells with Torin1 (Thoreen et al., 2012). Thirty-three percent of human homologs of mouse genes exhibiting decreased TE were bound by LARP1 in mTOR-inactive conditions compared to only 12% and 14% of genes showing no change in or increased TE, respectively (Figure 1—figure supplement 1E). We next wondered if increased pyrimidine richness observed at 3’ ends of LARP1-bound 5’UTRs is functionally linked to mTOR-dependent changes in TE rates. We compared 5’UTR pyrimidine content of mouse RP-encoding mRNAs exhibiting the greatest changes in TE to those exhibiting the least and saw no difference at the 5’-most region of the 5’UTRs (Figure 1—figure supplement 1F). Strikingly, however, the 3’-most 5’UTR region of the most affected genes contained a significantly higher proportion of pyrimidines compared to the least affected genes (Welch’s two-tailed t-test: p=0.036), indicating that pyrimidine richness at LARP1-interacting regions of 5’UTRs is correlated with strong decreases in TE upon mTOR inactivation. Together, these results suggest that the relationship between LARP1 binding and decreased TE is conserved from mouse to human.

Of the 88 annotated human ribosomal proteins, mRNAs encoding 84 were expressed in our mRNA-seq libraries under both conditions. Summing LARP1 binding site coverage of these genes confirms increased LARP1 binding at 5’UTRs and slightly decreased LARP1 binding at CDS and 3’UTR upon mTOR inactivation (Figure 1G). We verified the specific interaction between endogenous LARP1 and mRNAs encoding RpS6, S3A, S18, L26, and L32 by RNA immunoprecipitation (RIP) assays followed by quantitative PCR (qPCR) (Figure 1—figure supplement 1G). Taken together, these observations raise the intriguing possibility that the function of LARP1 in regulating RP mRNA translation may be context-dependent: the interaction of LARP1 with PESs in the 5’UTRs of RP mRNAs may have an inhibitory role, whereas its interaction with 3’UTRs may exert a positive role in RP mRNA translation.

To investigate the mechanisms by which site-specific LARP1 interaction with RP mRNAs is regulated by the activity of mTOR, we examined the roles of post-translational modifications of LARP1 regulated by mTOR activity. Previous genome-wide phospho-mass spectrometry analyses showed that LARP1 is a highly phosphorylated protein and has Torin1-sensitive phosphorylation sites (Hsu et al., 2011; Kang et al., 2013; Yu et al., 2011), suggesting that phosphorylation of LARP1 may regulate the configurations of LARP1-RP mRNA interaction. Phospho-mass spectrometry analysis targeting endogenous LARP1 revealed that more than 10 LARP1 phosphorylation sites, eight (highlighted by red color) of which were significantly sensitive to short-term Torin1 treatment (Figure 2A and Figure 2—figure supplement 1A), were identified. Among the Torin1-sensitive phosphorylation sites, two serine residues (Ser770 and Ser979), which follow the typical consensus motif (RxRxx[S/T]) for AGC kinases (Figure 2B), were directly phosphorylated by S6K1 or Akt in vitro (Figure 2C and D, and Figure 2—figure supplement 1B). Further, in vitro kinase assays using multiple polypeptides containing these Torin1-sensitive phosphorylation sites identified that Ser689 and Thr692, which do not match the AGC kinase phosphorylation motif (Figure 2B), were directly phosphorylated by mTOR (Figure 2E). These observations indicate that LARP1 is a direct substrate of mTOR, S6K, and Akt. Overexpression of active S6K1 or Akt induced phosphorylation of the RxRxx[S] motifs of wild type LARP1 but not the LARP1 2A mutant, where both Ser770 and Ser979 were substituted with alanine, in vivo (Figure 2F and G). Active Akt-induced LARP1 phosphorylation was not inhibited by rapamycin or S6K1 inhibitor (PF-4708671: PF), confirming that Akt is also able to directly phosphorylate LARP1 in vivo (Figure 2—figure supplement 1C). The phosphorylation of AGC kinase sites of LARP1 is sensitive to amino acids or amino acids/growth factor stimulation (Figure 2H). To investigate the functional roles of endogenous S6K1 and Akt in the phosphorylation of LARP1, we examined the phosphorylation status of LARP1 under acutely stimulated (growth factor/amino acid starvation for 60 min then stimulation with growth factor/amino acid for 10 min) or steady state growth conditions with or without the addition of rapamycin, Torin1, or a specific Akt inhibitor, MK-2206 (Figure 2I). Upon growth factor/amino acid stimulation, the phosphorylation of both Akt and S6K1 was enhanced compared to those under starvation conditions. Simultaneously, the phosphorylation of LARP1, as detected by both the Akt substrate antibody and the pS979 LARP1 antibody, was enhanced. Importantly, under this acutely stimulated condition, rapamycin, which completely inhibits S6K1, but not Akt, had little effect on S770/S979 phosphorylation of LARP1. In contrast, the Akt inhibitor MK-2206, as well as Torin1, which inhibit both Akt and S6K1, largely inhibited S770/S979 phosphorylation of LARP1.

Figure 2 with 1 supplement see all

Download asset Open asset

Under the steady state growth condition, inhibition of S6K1 with rapamycin or PF 4708671, a S6K inhibitor, equally and significantly decreased LARP1 phosphorylation, and Torin1 and MK-2206 further blocked these phosphorylations. Taken together, these observations indicate that Akt is a physiologically relevant primary kinase for S770/S979 phosphorylation of LARP1 especially under acute stimulatory conditions. Under steady state conditions, S6K plays a major role while Akt also partially contributes to the phosphorylation of LARP1 (Figure 2J).

Our PAR-CLIP data indicated that while LARP1 primarily interacts with 3’UTRs of RP mRNAs under growth conditions, it also binds to 5’UTRs of RP mRNAs upon mTOR inactivation (Figure 1C). To investigate the roles of LARP1 phosphorylation in binding RP mRNAs, we examined specific interactions between LARP1 and the 5’ or 3’UTR of RpL32 mRNA as a representative example of RP mRNAs bound by LARP1 identified in our PAR-CLIP analyses (Figure 1H). In agreement with our PAR-CLIP data, RIP assays demonstrated that endogenous LARP1 interacted with both the 5’UTR (closed bar) and 3’UTR (open bar) of RpL32 under amino acid starvation conditions (Figure 3A). In addition, in response to amino acids, which enhances mTORC1 activity, the interaction between LARP1 and the RpL32 5’UTR was decreased in a manner dependent on cellular mTOR kinase activity. In contrast, the binding of LARP1 to the RpL32 3’UTR was increased in response to mTOR activation.

Figure 3

Download asset Open asset

Importantly, phosphorylation of LARP1 (S689/T692 and S770/S979) identified in Figure 2 plays key roles in LARP1 binding to both the 5’ and 3’ UTRs of RpL32 mRNA. Similar to endogenous LARP1, the interaction of wild-type myc-LARP1 (closed bar) with the 5’UTR of RpL32 is decreased by amino acid stimulation in a manner dependent on mTOR activity (Figure 3B). However, alanine substitutions of mTOR (S689/T692) and S6K1/Akt (S770/S979) phosphorylation sites confer the LARP1 4A mutant (open bar) resistant to its dissociation from the 5’UTR in response to amino acid stimulation. Furthermore, the PES located at the 3’ end of the RpL32 5’UTR was essential for its interaction with LARP1 as substitutions of pyrimidines with guanines (5’conv) in the PES region within the 5’UTR (Figure 1H) dramatically reduced its interaction with both wild type LARP1 and LARP1 4A mutant even under amino acid starvation conditions (Figure 3B). The LARP1 14A mutant, which bears an additional 10 alanine substitutions in the phosphorylation sites identified in Figure 2A, also displayed enhanced binding to the 5’UTR of RpL32 mRNA, similar to the LARP1 4A mutant compared to wild type LARP1 under growth culture conditions (Figure 3C). These results indicate that phosphorylation of these four serine/threonine residues plays a key role in reducing the interaction of LARP1 with the 5’UTR of RpL32 mRNA through the PES. Further analyses revealed that both mTOR- and S6K1-dependent LARP1 phosphorylation were required to reduce its binding to the 5’UTR of RpL32 mRNA, while either mTOR- or S6K1-dependent phosphorylation of LARP1 was sufficient to maintain its association with the 3’UTR under steady state growth condition (Figure 3D). Consistently, the inhibition of S6K1 activity with PF-4709671 sufficiently blocked the reduction of LARP1’s binding to the 5’ UTR of RpL32 mRNA as did amino acid starvation, rapamycin or Torin1 treatment, which inhibits both S6K1 and mTORC1 activity. However, PF-470961 treatment alone failed to induce the dissociation of LARP1 from the 3’UTR of RpL32 mRNA (Figure 3E). Together with our PAR-CLIP data, these observations indicate that the affinity of LARP1 binding to the 5’ and 3’ UTR of RpL32 mRNA dynamically changes in a manner dependent on mTOR and S6K1/Akt-dependent phosphorylation.

To examine the configuration of LARP1 binding to the 5’UTR and 3’UTR of RpL32 mRNA, we performed PAR-CLIP assays using endogenous LARP1 with the reporter mRNAs containing both the 5’ and 3’UTR of RpL32 mRNA. Interestingly, under cross-linking conditions, LARP1 can bind the wild type (5’/3’) or the 5’UTR-mutated (5’conv/3’) reporter mRNA equally well in the presence or absence of Torin1 treatment, respectively (Figure 3F). These observations suggest that the same amount of LARP1 constantly interacts with the UTRs of RpL32 mRNA under both high and low mTOR activity conditions, although the affinity of LARP1 binding to the 5’ and 3’ UTR of RpL32 mRNA significantly changes in response to cellular mTOR/Akt activity. This raises the possibility that non-phospohrylated LARP1 may simultaneously interact with both the 5’ and 3’ UTR of the same RpL32 mRNA under low mTOR activity conditions while phosphorylated LARP1 dissociates from the 5’UTR and mainly interacts with the 3’UTR of RpL32 mRNA.

To examine the significance of LARP1 interaction with the 5’ or 3’UTR in the translation of RpL32 mRNA, we measured luciferase production from the indicated reporters (Figure 3G). Luciferase protein expression from the reporter containing both 5’ and 3’UTRs of RpL32 was consistently higher compared to the reporter with just 5’UTR, suggesting that the 3’ UTR is important for stimulating RpL32 translation. Both the 5’ UTR-mutated reporter (5’conv/3’) and the wild type reporter (5’/3’) generate similar levels of luciferase protein under growth conditions (Figure 3G, filled bars) that induce LARP1 dissociation from the 5’UTR. Importantly, under mild serum starvation conditions, the 5’UTR-mutated reporter (5’conv/3’) produces more luciferase protein compared to the wild type reporter (5’/3’) (Figure 3G, open bars). Furthermore, phosphorylatable wild type Myc-LARP1 showed some advantages in stimulating translation of the 5’conv/3’ reporter compared to the wild type 5’/3’ reporter in cells lacking endogenous LARP1 (Figure 3H). In contrast, the phopho-defective Myc-LARP1 4A mutant significantly and equally inhibited the translation of both reporters, regardless of the existence (5’/3’) or absence (5’conv/3’) of the LARP1 binding site in the 5’UTR in these cells. These observations indicate that the dissociation of LARP1 from the PES motif in the 5’UTR and the phosphorylation of LARP1, which enhances LARP1 binding to the 3’UTR, are important processes in stimulating RpL32 mRNA translation. Moreover, the data also suggest that the phosphorylation of LARP1 has an additional key role in stimulating the translation of RpL32 mRNA at the 3’UTR (see Figures 5 and 6). Note that the translation of the 5’conv/3’ mutant reporter was slightly, but significantly, enhanced compared to the 5’/3’ wild type reporter in cells expressing ectopic Myc-LARP1, which was not seen in the cells expressing just endogenous LARP1 (Figure 3G). We speculate that overexpressed Myc-LARP1 may not be fully phosphorylated in our experimental conditions. As a consequence, non-phosphorylated wild type LARP1 may still bind to the PES in the 5’UTR and reduce the translation of the wild type 5’/3’ reporter. Accordingly, cells expressing the LARP1 4A mutant, which strongly binds to the 5’UTR of RpL32 mRNA irrespective of cellular mTOR activity, have reduced expression of RP proteins including RpL32 (Figure 3I). Together with our PAR-CLIP data (Figure 1), these observations suggest that LARP1 stimulates RP mRNA translation through its interaction with the 3’UTR and that its association with the 5’UTR has a negative role in RP mRNA translation.

To stimulate the translation of 5’TOP mRNAs, previous studies have proposed that LARP1 directly interacts with initiation factors and polyA-binding protein (PABP) in response to mTORC1 activity (Aoki et al., 2013; Tcherkezian et al., 2014). In contrast, a more recent study proposed that active mTORC1 interacts with LARP1 and inhibits LARP1’s function to suppress translation initiation of LARP1-interacting 5’TOP mRNAs (Fonseca et al., 2015). Thus, the functional importance of LARP1-mTORC1 interaction and the role of LARP1 in the regulation of translation of LARP1-interacting mRNAs remain unclear. We also observed that endogenous as well as exogenous LARP1 specifically and stably interacts with mTORC1 through Raptor under growth conditions (Figure 4A and Figure 4—figure supplement 1A–C). LARP1 exclusively interacts with mTORC1 but not with mTORC2 (Figure 4A and Figure 4—figure supplement 1A). mTOR sufficiently co-IPs LARP1 only in the presence of endogenous Raptor (Figure 4—figure supplement 1B). In addition, Raptor is able to co-IP LARP1 in the presence of non-ionic detergent (NP-40), which is known to disrupt the interaction between Raptor and mTOR (Figure 4—figure supplement 1C). These results indicate that LARP1 association with mTORC1 requires Raptor.

Figure 4 with 1 supplement see all

Download asset Open asset

LARP1 also co-IPs PABP1, a polyA tail and eIF4G1 binding protein, as previously reported (Blagden et al., 2009; Burrows et al., 2010; Tcherkezian et al., 2014). However, whether LARP1 directly interacts with PABP1 or indirectly, perhaps through a common mRNA substrate, remains unresolved. To address the nature of LARP1 interaction with PABP1 and mTORC1, we treated cell lysates with RNaseA prior to or after LARP1 immunoprecipitation (Figure 4B and Figure 4—figure supplement 1D). As expected, LARP1 co-IPed not only mTORC1 and PABP1, but also eIF4E, a 5’CAP mRNA binding initiation factor. While LARP1 interaction with mTORC1 was resistant to RNaseA treatment, its interaction with PABP1 and eIF4E was markedly sensitive to RNaseA treatment. (Figure 4B and Figure 4—figure supplement 1D). In addition, eIF4G1, a scaffolding protein for forming the eIF4F complex, co-IPed other eIF4F components and LARP1 (Figure 4B). Although the interaction between eIF4G1 and other eIF4F components such as eIF4E, eIF3B, and PABP1 was RNaseA resistant, the binding of eIF4G1 to LARP1 was abolished by the treatment with RNaseA. Interestingly, LARP1 coIPed more mTORC1 from lysates treated with RNaseA than in untreated lysates (Figure 4B and Figure 4—figure supplement 1D), suggesting that a substantial pool of the mTORC1-LARP1 complex is refractory to IP with the LARP1 antibody under standard lysis conditions and may exist in an RNaseA-sensitive pool. Taken together, these data indicate that LARP1 indirectly associates with PABP1 and initiation factors through binding of common mRNAs, while LARP1-mTORC1 interaction occurs through direct protein-protein contacts.

Importantly, the activity of mTORC1 plays a key role in LARP1’s binding to mTORC1 but not to PABP1. LARP1 failed to interact with mTORC1 but maintained its interaction with PABP1 subjected to mTOR inhibitors, suggesting that LARP1 associates with mRNAs regardless of cellular mTOR activity (Figure 4D), consistent with our PAR-CLIP data (Figure 1C). Furthermore, the interaction between endogenous LARP1 and mTORC1 was quickly and fully restored by replenishment of amino acids and growth factors after starvation of these activating cues, whereas the interaction between LARP1 and PABP1 was not affected by these cues (Figure 4E). Furthermore, recovery of the interaction between LARP1 and mTORC1 by growth factor/nutrient stimulation occurred concomitantly with 4EBP1 phosphorylation but precedes full phosphorylation of S6K1.

To investigate the mechanisms underlying the formation of the LARP1-mTORC1 complex, we determined regions of LARP1 necessary to associate with mTORC1. Interestingly, serial truncations of the LARP1 carboxyl terminus revealed that the DM15 motif and an N-terminal region adjacent to the DM15 motif (Figure 5A), where the majority of Torin1-sensitive LARP1 phosphorylations occur (Figure 2A), were critical for its association with mTORC1. The LARP family of proteins consists of six members comprised of LARP1, 2 (1B), 4, 5 (4B), 6, and 7 (Figure 5—figure supplement 1) (Bousquet-Antonelli and Deragon, 2009). Consistently, only LARP1 and LARP2, both of which possess the DM15 motif and an adjacent N-terminal region, interacted with mTORC1 (Figure 5B). Although LARP2, a close LARP1 paralog (59% amino acid sequence identity), interacted with mTORC1, its affinity for mTORC1 was significantly weaker than LARP1. These data suggest that the phosphorylations of LARP1 may also play an important role in maintaining LARP1-mTORC1 interactions, in addition to their roles in the binding of LARP1 with RP mRNAs.

Figure 5 with 1 supplement see all

Download asset Open asset

To examine the role of LARP1 phosphorylation in the regulation of interaction between LARP1 and mTORC1, we first assessed mTORC1 binding with a series of phospho-defective LARP1 mutants (S689/T692A: mTOR sites, S770/S979A: Akt/S6K1 sites, and 4A: mTOR and Akt/S6K1 sites). While the replacement of LARP1 Akt/S6K1 phosphorylation sites with alanines only slightly reduced LARP1 interaction with mTORC1, mutations in the LARP1 mTOR phosphorylation sites largely abrogated its interaction with mTORC1 (Figure 5C). Importantly, both the wild type and LARP1 4A mutant were able to associate with PABP1 equally well through their binding to common mRNAs; however, PABP1 co-IPed mTORC1 only in the presence of wild-type LARP1 but not the LARP1 4A mutant (Figure 5D). These observations suggest that LARP1 phosphorylation by mTORC1 is critical for tethering mTORC1 to the LARP1-mRNP complex. In support of this hypothesis, under growth conditions where phosphorylated LARP1 mainly binds to the 3’UTRs of RP mRNAs (Figures 1B, C and 3A), mTORC1 associated more with the 3’UTR than the 5’UTR of RpL32 mRNA in Raptor CLIP assays (Figure 5E). mTORC1 association with RpL32 mRNA was dependent on wild type LARP1 but not the LARP1 4A mutant (Figure 5F). Moreover, wild type LARP1 supports greater association of mTORC1 with its substrates S6K1 and 4EBP1 than the LARP1 4A mutant (Figure 5G and H). Taken together, these data suggest that while non-phosphorylated LARP1 blocks RP mRNA translation through its interaction with the 5’UTR of RP mRNAs, phosphorylated LARP1 is converted into a scaffolding protein for mTORC1 on the 3’UTRs of RP mRNAs to facilitate the accessibility of mTORC1 with 4EBP1 and S6K1.

To further investigate the roles of LARP1 in mTORC1-dependet phosphorylation of its substrates, endogenous LARP1 was knocked down in mammalian cells with varying degrees of insulin sensitivity. In HEK293T cells (insulin insensitive), ablation of LARP1 slightly decreased phosphorylation of S6K1, S6, and 4EBP1 compared to those in control cells under normal growth culture conditions (Figure 6—figure supplement 1A). However, in response to growth factor/amino acids stimulation, LARP1 knockdown significantly delayed and attenuated phosphorylation of these proteins in HEK293T cells (Figure 6A and Figure 6—figure supplement 1A), LnCap (prostate cancer cell line) (Figure 6—figure supplement 1B), and HEK293E cells (insulin sensitive) (Figure 6—figure supplement 1C). In contrast, Akt phosphorylation (Ser473) was not affected by the ablation of LARP1, indicating that the activity of PI3K and mTORC2 was intact in the LARP1 knockdown cells. In addition, LARP1 knockdown had little effect on intrinsic mTOR kinase activity monitored by mTOR auto-phosphorylation (Ser2481) (Figure 6A, Figure 6—figure supplement 1A–C) (Copp et al., 2009; Peterson et al., 2000), or on the integrity of mTORC1 and its kinase activity as measured by in vitro kinase assays (Figure 6—figure supplement 1D). The inhibitory effects of LARP1 knockdown on inducible S6K1 and 4EBP1 phosphorylation were not due to a disruption of eIF4F-mediated translation because knockdown of eIF4G1, which plays a key role in mTORC1-dependent translation (Thoreen et al., 2012), did not affect S6K1, S6, or 4EBP1 phosphorylation (Figure 6B).

Figure 6 with 1 supplement see all

Download asset Open asset

Immunostaining of LARP1 and phosphorylated forms of 4EBP1 and S6 revealed that endogenous LARP1 was predominantly expressed in the cytoplasm where 4EBP1 and S6 phosphorylation occurs in response to growth factor and nutrient stimulation (Figure 6C). In addition, LARP1 did not colocalize with LAMP2 on the lysosomal membrane, where mTORC1 is activated. Consistent with the biochemical observations (Figure 6A and Figure 6—figure supplement 1A–C), LARP1 knockdown significantly reduced growth factor/nutrient-induced phosphorylation of 4EBP1 and S6 (Figure 6C). Notably, LARP1 knockdown (Figure 6—figure supplement 1E) or ectopic expression (Figure 6D) did not alter amino acid-induced mTORC1 localization on the lysosomal membrane, suggesting that, in addition to growth factor-induced PI3K/Akt activity, the amino acid-sensing mechanism on lysosomal membranes also remains intact in LARP1 knockdown and overexpressing cells. In response to amino acids, co-localization of Flag-LARP1 with mTOR became more obvious in cytosolic regions but not on the lysosomal membrane (Figure 6D, lower panels). Taken together, these data support the idea that phosphorylated LARP1 facilitates mTORC1-dependent phosphorylation of S6K1 and 4EBP1 on the LARP1-containing mRNPs by scaffolding mTORC1.

In agreement with the results of Figure 6A, m⁷GTP pull down assays showed that the interaction of 4EBP1 with eIF4E was increased in LARP1 knockdown cells (Figure 7A), suggestive of increased levels of non-phosphorylated 4EBP1 in LARP1 knockdown cells. Consistently, LARP1 knockdown partially decreased eIF4E in fractions containing pre-initiation complex (43S and 48S: fraction 5 and 6) while Torin 1, an mTOR kinase inhibitor, largely eliminated eIF4E from these fractions (Figure 7B). These data indicate that a fraction of cellular translation initiation is decreased in LARP1 knockdown cells. However, intriguingly, RP mRNAs that interact with LARP1 accumulated more in lighter polysome fractions in LARP1 knockdown cells compared to control cells under normal growth conditions (Figure 7C). In control cells, acute nutrient/growth factor starvation selectively redistributes RP mRNAs from the polysome fractions to the monosome (80S) fraction (Figure 7C, middle panels). In contrast, under the same starvation conditions, LARP1 knockdown results in retention of a substantial portion of RP mRNAs in the polysomes fractions while attenuating the accumulation of RP mRNAs in the monosome fraction (Figure 7C, middle panels). These observations suggest that RP mRNA translation is less sensitive to the inhibition caused by growth factor/nutrient depletion in LARP1 knockdown cells. Furthermore, replenishing growth factors and nutrients following identical starvation conditions showed similar RP mRNA distribution in polysome fractions in both control and LARP1 knockdown cells (Figure 7C, right panels). These results suggest that both ribosome dissociation from RP mRNAs and ribosome loading on RP mRNAs are inefficient, and that ribosome stalling may occur during RP mRNA elongation in LARP1 knockdown cells. However, non-LARP1 interacting mRNAs such as FOXO1 and YBX1 did not accumulate in polysome fractions in LARP1 knockdown cells, indicative of the specific roles of LARP1 in preventing ribosome stalling during the translation of LARP1 interacting mRNAs (Figure 7—figure supplement 1A). Indeed, in cells subjected to short-term LARP1 knockdown, the expression of eEF2 in the 80S monosome and polysome fractions was reduced (Figure 7B). Taken together, these data suggest that the efficiency of translation elongation of LARP1-interacting mRNAs is likely to be compromised in LARP1 knockdown cells.

Figure 7 with 2 supplements see all

Download asset Open asset

To assess directly the flux of RP mRNA translation, we measured the rate of de novo RP protein synthesis. In vivo labeling experiments revealed that knockdown of LARP1 significantly reduced the levels of newly synthesized RP proteins (Figure 7D). Furthermore, prolonged LARP1 knockdown decreased RP protein expression (Figure 7E) and reduced global protein synthesis (Figure 7F) without significantly affecting levels of RP mRNAs. In multiple cancer cell lines (PC3 (prostate), SW40 (colon), HeLa (cervix), and MDA MB231 (breast)), expression levels of LARP1 and RP proteins were well correlated and often enhanced compared to those in non-transformed normal cells (human normal fibroblasts: HNF, and human normal prostate epithelial cells: PrEC) (Figure 7G, left upper panels). Furthermore, there was an especially clear trend of higher LARP1 and RP protein expression in multiple prostate cancer cell lines (LnCap, 22RV1, PC3, and Du145) compared with those in non-transformed (PrEC) or transformed (PTN2 and RWPE) normal prostate epithelial cells (left lower panels). Again, there was clear positive correlation between the expression of LARP1 and the RP proteins (e.g. RpS6, right upper panel) but not between LARP1 protein and RpS6 mRNA (right lower panel) in prostate cancer and normal cells. Finally, as previously demonstrated in other cancer cell lines (Burrows et al., 2010; Hopkins et al., 2016; Tcherkezian et al., 2014), the ablation of LARP1 largely blocked cell proliferation in multiple cancer cell lines including prostate cancer cells (Figure 7—figure supplement 1B). Together, these observations indicate that LARP1 functions as a phosphorylation-sensitive switch for inhibiting or stimulating the translation of RP mRNAs in response to the mTOR activity (Figure 7—figure supplement 2), thereby titrating cellular ribosomes and the capacity of cellular protein synthesis.

Antibodies were purchased from the following sources: Antibodies to mTOR (cat. # 2983, RRID:AB_2105622 for western blotting and immunostaining), Raptor (cat. # 2280, RRID:AB_561245), pT389 S6K1 (cat. # 9206, RRID:AB_2285392), S6K (cat. # 9202, RRID:AB_823592), pS473 Akt (cat. # 9270, RRID:AB_329824), Akt (cat # 9272, RRID:AB_329827), phospho-Akt Substrate (RXXS/T) (cat. # 9614, RRID:AB_2225188), pT37/46 4EBP1 (cat. # 2855, RRID:AB_560835), 4EBP1 (cat. # 9644, RRID:AB_10691384), S6 (cat. # 2217, RRID:AB_331355), pS235/236 S6 (cat. # 4856, RRID:AB_2181037 for western blotting), pS240/244 S6 (cat. # 5364, RRID:AB_10694233 for co-IP), RpL13a (cat. # 2765, RRID:AB_916223), PABP1 (cat # 4992, RRID:AB_2156887), mLST8 (cat. # 3274, RRID:AB_823685), PRAS40 (cat. # 2610, RRID:AB_916206), pULK1 (cat. # 6888, RRID:AB_10829226), and ULK1 (cat. # 6439, RRID:AB_11178933) from Cell Signaling Technology; antibodies to LARP1 (cat. # A302-087A, RRID:AB_1604274 for co-IP and western blotting, cat. # A310-088A, RRID:AB_2632225 for IP and western blotting and cat. # IHC-00559, RRID:AB_10631280 for immunostaining), Rictor (cat. # A300-458A, RRID:AB_420924), eIF4G (cat. # A301-776A, RRID:AB_1211011), eIF3D (cat. # A301-758A, RRID:AB_1210970), and eIF3B (cat. # A301-761A, RRID:AB_1210995) from Bethyl Laboratories; antibodies to eIF4E (cat. # sc-9976, RRID:AB_627502) and mTOR/FRAP (cat. # sc-1549, RRID:AB_631981 for co-IP) from Santa Cruz Biotechnology; antibodies to β-Actin (cat. # A1978, RRID:AB_476692), and Flag M2 antibodies (cat. # F1804, RRID:AB_262044) from Sigma-Aldrich; antibodies to HA tag (cat. # MMS-101P, RRID:AB_2314672), and Myc tag (cat. # MMS-150P, RRID:AB_291322) from Covance; antibody to LAMP2 (cat. # H4B4, RRID:AB_528129) from the Developmental Studies Hybridoma Bank at the University of Iowa; HRP-conjugated mouse secondary antibody (cat. # NA931-1ML, RRID:AB_772210) and HRP-conjugate rabbit secondary antibody (cat. # NA934-1ML, RRID:AB_772206) from GE Healthcare; Alexa fluor 594 goat anti-rabbit IgG (cat. # A11012, RRID:AB_141359) and Alexa fluor 488 goat anti-mouse IgG (cat. # A11001, RRID:AB_2534069) from Invitrogen.

HEK293T and HEK293E (a generous gift from Dr. Diane Fingar, University of Michigan) cells (Tee et al., 2002) were cultured in DMEM with 10% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin (Invitrogen). Human breast cancer cell line: MDA-MB-231 cells (kindly provided by Dr. Shaomeng Wang, University of Michigan) (Lu et al., 2008), human colon cancer cell line: SW480 cells (kindly provided by Dr. Eric Fearon, University of Michigan) (Mazzoni et al., 2015), and human prostate cancer cell lines: LNCaP, 22RV1 and PC3 and benign prostate cell lines: PNT2 and RWPE (generous gifts from Dr. Arul Chinnaiyan, University of Michigan) (Ateeq et al., 2011; Helgeson et al., 2008; Tomlins et al., 2007) were cultured in RPMI 1640 with 10% FBS and 100 units/ml penicillin/streptomycin and RWPE cells were cultured in keratinocyte serum-free medium (Invitrogen) with Supplements for Keratinocyte-SFM (Invitrogen). Primary prostate cell line: PrEC was purchased from LONZA and cultured in the PrEGM media (LONZA). Each cell line was tested for mycoplasma contamination and confirmed the absence of mycoplasma using fluorescence- and PCR-based methods (Invitrogen) before subjecting to the experiments. In order to inhibit kinases involved in the PI3K pathway we treated cells with 250 nM Torin-1, 20 μM PF 470861 (Tocris bioscience), 2.5 μM PP242 (Sigma-Aldrich), 100 μM rapamycin (LC laboratories), 1 μM Akt1/2 inhibitor (Sigma-Aldrich), or 2 μM MK-2206 (Active BioChem) for indicated times. For growth factors/nutrients starvation, cells were incubated with either HBSS (Hank’s Balanced Salt Solution, Invitrogen) or DPBS (Dulbecco’s Phosphate-Buffered Saline, Invitrogen) for the indicated times. For stimulation of these, growth media were added for the indicated times.

Cells were harvested with CHAPS lysis buffer (40 mM HEPES [pH 7.5], 120 mM NaCl, 1 mM EDTA, 0.3% CHAPS, and 20 mM glycerophosphate, 10 mM NaF, 10 mM sodium pyrophosphate [Sigma-Aldrich] and EDTA-free protease inhibitor [Roche]) by incubating on ice for 15 min. The soluble fractions were isolated by centrifugation at 14,000 rpm for 15 min at 4°C. For immunoprecipitation, 1 µg of antibodies was added and incubated with gentle rocking for 3–6 hr at 4°C. 20 µl of 50% slurry of protein G sepharose (GE Healthcare) was added and incubated for additional 1 hr. Immunoprecipitates were washed with CHAPS lysis buffer for five times and then denatured at 100°C for 5 min in 1X SDS sample buffer. For RNase A treatment, lysates were incubated with 20 μg of RNase A (Affymetrix) for 1 hr at room temperature with gentle rocking. After spinning at 14,000 rpm at 4°C for 15 min to remove protein aggregates, remaining supernatant was applied for further analysis. For immunostaining, cells on round cover slips (Fisher Scientific) were fixed with 4% paraformaldehyde for 20 min and washed with PBS three times. Fixed cells were permeabilized with 0.2% TX-100 for 10 min at room temperature and blocked in 2% BSA in PBS for 1 hr. After washing with PBS three times, cells were incubated with indicated primary antibodies for three hours at room temperature and washed with PBS three times. Cells were incubated with Alexa fluor 488/594 goat anti-mouse/rabbit IgG for 1 hr at room temperature. Cells were washed with PBS three times and once with water. The cover slips were mounted on the glass slides using ProLong Gold antifade reagent with DAPI (Life technologies) and imaged with 63X oil-immersion objective by using a Leica TCS SP5 confocal microscope.

To label cells with 4-thiouridine (4-SU), cells were seeded in two 15 cm plates to grow overnight to reach 70% confluency. On the next day, cells were incubated with 100 μM 4-SU for 14 hr. After washing with cold PBS, cells were irradiated in the CL-1000 ultraviolet Crosslinker (UVP) on ice with 150 mJ/cm². Cross-linked cell pellets were collected by scraping and lysed with 600 μl PAR-CLIP lysis buffer (0.1% SDS, 0.5% deoxycholate, 0.5% NP-40 in PBS without Mg²⁺, Ca²⁺) on ice for 10 min. To remove DNA, 10 μl of RQ1 DNAse was added into each tube and tubes were incubated at 37°C for 10 min with gentle rocking. Afterward, 1 U/µl of RNase T1 (Fermentas) was added and the lysates were incubated at room temperature for 15 min with gentle rocking. Lysates were spun at 4°C for 10 min at 14,000 rpm. The soluble fractions were incubated with LARP1 antibody-Dynabeads Protein A for 1 hr at 4°C. Immunoprecipitates were collected on a magnetic stand and were then washed three times with IP-wash buffer (50 mM HEPES-KOH [pH 7.5], 300 mM KCl, 0.05% NP-40, 0.5 mM DTT, and EDTA-free protease inhibitor). Immunoprecipitates were resuspended in 40 μl of IP wash buffer containing 50 U/μl RNase T1 (Fermentas) and incubated at room temperature with gentle rocking for 15 min followed by incubation on ice for 5 min. Immunoprecipitates were washed with high-salt wash buffer (50 mM HEPES-KOH [pH 7.5], 500 mM KCl, 0.05% NP-40, 0.5 mM DTT, and EDTA-free protease inhibitor), three times with the PAR-CLIP lysis buffer, and twice with high-salt wash buffer (0.1% SDS, 0.5% deoxycholate, 0.5% NP-40 in 5X PBS without Mg²⁺, Ca²⁺) followed by washing twice with PNK (polynucleotide kinase) buffer (50 mM Tris-Cl pH 7.4, 10 mM MgCl₂, 0.5% NP-40). For visualization of crosslinked RNAs, immunoprecipitates were incubated in 40 μl of the PNK mixture (1 μl of P³²γATP, 4 μl of 10X PNK buffer [NEB], 2 μl of T4 PNK enzyme [NEB], 33 μl of water) for 30 min at 37°C. Labeled immunoprecipitates were washed three times with PNK buffer and resuspended with 30 μl of 2X NuPAGE LDS sample buffer (15 μl of 1 X PNK with 15 μl of Novex LDS sample buffer). Denatured samples were resolved in 4–12% NuPAGE Bis-Tris gel and transferred to nitrocellulose membrane at 30 V for 1 hr using NuPAGE transfer buffer. The membrane was exposed to X-ray film at −80°C for 4 hr to visualize crosslinked RNAs. Molecular biology procedures for cloning LARP1-bound RNA fragments was described previously (Freeberg et al., 2013).

PAR-CLIP-seq and mRNA-seq reads were processed to remove linkers. All reads were mapped to the human transcriptome version GRCh37 using Bowtie (Langmead et al., 2009) allowing for up to three mismatches with the following parameters: -v 3 k 100 --best --strata --phred33-quals. mRNA-seq reads mapping perfectly to the transcriptome were kept; reads mapping perfectly to multiple loci were distributed evenly among the mapped positions. Transcript RPKM values were calculated as the number of reads per million mapped reads aligning to a transcript normalized to transcript length in kilobases. Replicate mRNA-seq libraries had a high Pearson correlation coefficient (R² = 0.99975), so transcript RPKM values were averaged from the two libraries. PAR-CLIP-seq reads with 0–2 T-to-C mismatches were clustered into peaks with at least one overlapping nucleotide. Clusters were smoothed with a Gaussian smoothing technique as described in (Freeberg et al., 2013) Clusters with at least one read containing a T-to-C conversion event were kept as LARP1 binding sites, and all reads containing 0–2 T-to-C conversion events were summed per binding site and normalized to the number of million mapped reads per library (RPM). The RPM of binding sites located in genic regions were additionally normalized to the gene RPKM and multiplied by 1000 to account for the kilobase normalization of gene RPKM values.

GO term enrichment analysis was performed using the topGO Bioconductor package for R. The background gene list was restricted to genes with reads in at least one of our replicate mRNA-seq libraries. The Fisher’s exact test was used to measure the significance of enriched GO terms, and p-values were corrected for multiple testing using the Bonferroni correction method. GO terms with adjusted p-values<0.001 were submitted to REVIGO (Supek et al., 2011) which summarizes long lists of GO terms (accompanied by enrichment p-values) by removing redundant terms and grouping terms into larger categories. REVIGO parameters were: allowed similarity = 0.9, database with GO term sizes: Homo sapiens, semantic similarity: SimRel. From these REVIGO-derived categories, GO terms were manually grouped into the following categories: translation, cell differentiation and development, protein localization to the ER, regulation of signaling response, response to stimulus, antibody production, metabolism, and other (Supplementary file 2). For example, the categories ‘translational elongation’, ‘translational initiation’, and ‘translation’ were all grouped into the ‘translation’ super-category. Genes are considered ‘translation-related’ if they are annotated to at least one of the GO terms in our translation super-categry.

Sequence motifs were searched for within the 198 and 186 5’UTR LARP1 binding sites found under growing and mTOR inactive conditions, respectively, using MEME with default parameters (Bailey et al., 2009) Binding site sequences were extended by 15nt up- and down-stream for this search. Additionally, sequence motifs were searched for within CDS and 3’UTR LARP1 binding sites under growing and mTOR inactive conditions using the same parameters.

Cells were seeded in 6-well plates a day before labeling to reach 70% confluency on the day of labeling. Cells were washed twice with warm methionine/cysteine free DMEM with 1 x L-glutamine (Invitrogen) and incubated with methionine/cysteine free DMEM with 1 X L-glutamine and 10% dialyzed FBS (Invitrogen) for 1 hr. Cells were labeled with 25 μM Click-IT AHA (L-Azidohomoalanine) for 4 hr in a CO₂ incubator. Labeled cells were washed once with PBS and lysed with NP-40 lysis buffer (10 mM Tris-Cl [pH 7.5], 2 mM EDTA, 100 mM NaCl, 1% NP-40, 50 mM NaF, 10 mM sodium pyrophosphate and EDTA-free protease inhibitor) for 10 min on ice. The soluble fractions isolated by centrifugation were transferred into new tubes and the Click-IT reaction was performed in 1 X Click-IT reaction buffer according to the manufacturer’s guide. The Click-IT reaction was stopped by addition of SDS sample buffer and denatured by boiling. Samples were resolved by SDS-PAGE and transferred to PVDF membrane for immunoblot analysis. Labeled proteins were probed with Avidin-HRP (BioRad) and membranes were visualized by ECL on x-ray film. Intensity of signal was quantified by Image J.

Prior to lysis, cells were treated with 100 µg/mL cycloheximide (CHX) for 5 min and washed with cold PBS containing 100 µg/mL CHX. Cells were harvested in 1 ml of cold PBS containing 100 µg/mL CHX. Cell pellets were resuspended in hypotonic buffer (5 mM Tris [pH 7.5], 2.5 mM MgCl₂, 1.5 mM KCl, 0.3% CHAPS, 20 mM glycerophosphate, 10 mM NaF, 10 mM sodium pyrophosphate and EDTA-free protease inhibitor) containing 100 µg/mL CHX, 2 mM DTT, and 200 U/ml RNasin (Promega) by vortexing for 5 s. Supernatants were collected by centrifugation for 10 min at 14,000 rpm, 4°C, and the A₂₆₀ of lysates was measured to normalize RNA levels. Lysates of 30 O.D.₂₆₀ were loaded on 10–50% sucrose density gradients (100 mM HEPES [pH 7.6], 1M KCl, 50 mM MgCl₂, 100 µg/mL CHX, 200 U/ml RNasin, and EDTA-free protease inhibitor) and centrifuged at 35,000 rpm for 3 hr at 4°C. Gradients were fractionated and the optical density at 254 nm was recorded using an ISCO fractionator (Teledyne ISCO). For immunoblotting, the fractions were concentrated by Vivaspin concentrator (Sartorius). For quantitative PCR normalization, 5 ng of luciferase control mRNA (Promega) was added to each fraction. RNA was extracted using TRIzol and cDNA was synthesized by SuperScript III First-Strand Synthesis System (Invitrogen) following the manufacturer’s instructions.

For mTOR in vitro kinase assays, HEK293T cells were lysed with CHAPS lysis buffer and endogenous mTOR, Flag-mTOR Wt (wild type), or Flag-mTOR KD (kinase defective) was immunoprecipitated and subjected to in vitro kinase assays. For LARP1 phosphorylation, the kinase reaction was performed in kinase reaction buffer (25 mM HEPES [pH 7.4], 50 mM KCl, 10 mM MgCl2, 200 mM cold ATP and 5 µCi of ³²PγATP) using 2 µg of GST-LARP1 fragment (654–731 aa) purified from bacteria. For 4EBP1 phosphorylation, 200 ng of GST-4EBP1 (full length) was used as a substrate for the kinase reaction without using ³²PγATP, and the phosphorylation of 4EBP1 was detected by the indicated phospho-specific 4EBP1 antibody. For AKT and S6K1 kinase assays, AKT-HA, AKT-HA KD, HA-S6K1 F5A 3DE (constitutive active), or HA-S6K1 KD was immunoprecipitated from HEK293T cells and kinase reactions were performed in the AKT/S6K1 kinase reaction buffer (75 mM Tris-Cl [pH 7.5], 15 mM MgCl₂, 1.5 mM DTT, 1.5 μg/ml BSA, 200 mM cold ATP and 5 µCi of P³²γATP) using 2 µg of GST-LARP1 fragments (722–822 aa or 929–1019 aa).

Short-hairpin RNAs (shRNAs) against LARP1 or eIF4G1 were cloned into the lentivirus plasmid pLKO.1-puro. HEK293T cells were transfected with pLKO.1-puro cloned with shRNA, psPAX2 (packaging plasmid) and pMD2 (envelope plasmid) using the calcium phosphate method. Lentivirus-containing supernatants were collected and spun at 23,000 rpm for 90 min. Virus pellets were resuspended with Opti-MEM (Invitrogen). Cells were infected for 24 hr and selected with 2 μg/ml puromycin for additional 24 hr. 72 hr post-infection, stably knocked-down cells were harvested and processed for further analysis.

shRNA scramble (control):

Sense:

5’CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTC3’

Antisense:

5’AATTGAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTA

ACCTTAGG3’ shRNA LARP1 UTR-2:

Sense:

5’CCGGGGTGAGGACTTCATCTCAACACTCGAGTGTTGAGATGAAGTCCTCACCTTTTTC3’

Antisense:

5’AATTGAAAAAGGTGAGGACTTCATCTCAACACTCGAGTGTTGAGATGAAGTCCTCACC3’ shRNA LARP1-3

Sense:

5’CCGGGCCAGTCTCAGGAGATGAACACTCGAGTGTTCATCTCCTGAGACTGGCTTTTTC3’

Antisense:

5’AATGAAAAAGCCAGTCTCAGGAGATGAACACTCGAGTGTTCATCTCCTGAGACTGGC3’ shRNA eIF4G1-1

Sense:

5’CCGGGGATCCCACTAGACTACAAGGCTCGAGCCTTGTAGTCTAGTGGGATCCTTTTTC3’

Antisense:

5’AATTGAAAAAGGATCCCACTAGACTACAAGGCTCGAGCCTTGTAGTCTAGTGGGATCC3’

RpS6:

Forward: 5’TGTCCGCCTGCTACTGAGTAA3’

Reverse: 5’GCAACCACGAACTGATTTTCTC3’

RpS3A:

Forward: 5’AGGGTCGTGTGTTTGAAGTGA3’

Reverse: 5’CATGGAAGTTAGTCAGGCAGTTT3’

RpS18:

Forward: 5’GCGGGAGAACTCACTGAGG3’

Reverse: 5’CGTGGATTCTGCATAATGGTGAT3’

RpL26:

Forward: 5’GACTTCCGACCGAAGCAAGAA3’

Reverse: 5’TGCACCCGTTCAATGTAGATAAC3’

RpL32:

Forward: 5’GCCCAAGATCGTCAAAAAGAGA3’

Reverse: 5’TCCGCCAGTTACGCTTAATTT3’

Actin:

Forward: 5’CATGTACGTTGCTATCCAGGC3’

Reverse: 5’CTCCTTAATGTCACGCACGAT3’

GAPDH:

Forward: 5’TTGCCATCAACGACCCCTTC3’

Reverse: 5’TTGTCATGGATGACCTTGGC3’

Firefly luciferase:

Forward: 5’CTCACTGAGACTACATCAGC3’

Reverse: 5’TCCAGATCCACAACCTTCGC3’

Forward: 5’gcctacggaggtggcagGGTAGtccttctcggcatc3’

Reverse: 5’gatgccgagaaggaCTACCctgccacctccgtaggc3’

Data are representative of at least two independent experiments. All values were given as means±SEM from three independent biological replicates. Comparisons were performed using Student’s t-test or one-way factorial ANOVA followed by Bonferroni’s post-hoc analysis.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

We thank Arul Chinnaiyan and Shaomeng Wang for providing breast and prostate cancer cell lines, respectively, Eric Fearon for helpful advice, Ivan Topisirovic for instructions on polysome fractionation, Aristotle Mannan for technical assistance, and Philip Gafken (Fred Hutchinson Cancer Research Center) for proteomic analyses. This work was supported by grants from the NIH (DK083491/GM110019 to KI, GM088565 to JKK), DOD (TS140055 to KI), and ACS Research Scholar Grant (to JKK) and the Ruddon Research Fund in Cancer Biology (to KI).

1. Received: January 19, 2017
2. Accepted: June 15, 2017
3. Version of Record published: June 26, 2017 (version 1)

© 2017, Hong et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.